{Reference Type}: Journal Article
{Title}: Controlled release of vitamin A palmitate from crosslinked cyclodextrin organic framework for dry eye disease therapy.
{Author}: Ye X;Li F;Li M;Zhang G;Wang W;Wang Z;Zhang H;Dong L;Lin X;Wu L;Peng C;Wang L;Chen W;Zhang J;
{Journal}: Int J Pharm
{Volume}: 659
{Issue}: 0
{Year}: 2024 Jun 25
{Factor}: 6.51
{DOI}: 10.1016/j.ijpharm.2024.124279
{Abstract}: Controlled release drug delivery systems of eye drops are a promising ophthalmic therapy with advantages of good patient compliance and low irritation. However, the lack of a suitable drug carrier for ophthalmic use limits the development of the aforementioned system. Herein, the crosslinked cyclodextrin organic framework (COF) with a cubic porous structure and a uniform particle size was synthesized and applied to solidify vitamin A palmitate (VAP) by using the solvent-free method. The VAP@COF suspension eye drops were formulated by screening co-solvents, suspending agents, and stabilizing agents to achieve a homogeneous state and improve stability. According to the in vitro release study, the VAP@COF suspension exhibited a controlled release of VAP within 12 h. Both the ex vivo corneal contact angle and in vivo fluorescence tracking indicated that the VAP@COF suspension prolonged the VAP residence time on the ocular surface. This suspension accelerated the recovery of the dry eye disease (DED) model in New Zealand rabbits. Furthermore, the suspension was non-cytotoxic to human corneal epithelial cells and non-irritation to rabbit eyes. In summary, the particulate COF is an eye-acceptable novel carrier that sustains release and prolongs the VAP residence time on the ocular surface for DED treatment.